Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Alfasigma S.p.A.
Hyundai Bioscience’s niclosamide-based oral antiviral moves into Phase II, joining other Korean COVID-19 treatment candidates in the pivotal trial stages, while SK Bioscience’s Phase III recombinant protein vaccine gears up for global market entry.
Public Company Edition: The last biopharma IPO in the US was on 17 February and none have been scheduled, so far, for March. Also, another SPAC merger is called off, Travere sells $275m worth of notes and Xeris secures $150m in new debt, while Ovid, Passage Bio and others are cutting jobs.
Seven international translational research bodies recommend five actions to help better prepare for future outbreaks. Plus an overview of recent COVID-19-focused collaborations.
Confirming rumors of an acquisition, CSL will venture into some new territories as well as boost its renal franchise when it takes over Switzerland’s Vifor Pharma in a deal worth $11.7bn.
- Other Names / Subsidiaries
- Defiante Farmaceutica S.A.
- Sigma-Tau Pharma Ltd
- Sigma-Tau Arzneimittel GmbH
- Sigma-Tau Research Switzerland SA
- Biofutura Pharma S.p.A.
- Alfa Wassermann SpA